Lv7
4790 积分 2025-08-19 加入
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
1个月前
已完结
Guselkumab: First Global Approval
1个月前
已完结
Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis
1个月前
已完结
Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis
1个月前
已完结
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
1个月前
已完结
Involvement of IL-17F via the induction of IL-6 in psoriasis
1个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
3个月前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
9个月前
已完结
Left ventricular ejection performance and systolic muscle function in patients with mitral stenosis
9个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1年前
已完结
皖公网安备34019202002308
